Exact Sciences Corporation $EXAS Shares Sold by Eagle Health Investments LP

Eagle Health Investments LP trimmed its position in Exact Sciences Corporation (NASDAQ:EXAS) by 42.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,750 shares of the medical research company’s stock after selling 164,900 shares during the period. Exact Sciences comprises about 2.9% of Eagle Health Investments LP’s investment portfolio, making the stock its 14th largest position. Eagle Health Investments LP owned about 0.12% of Exact Sciences worth $11,890,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of EXAS. Private Advisor Group LLC lifted its stake in shares of Exact Sciences by 39.2% during the first quarter. Private Advisor Group LLC now owns 31,742 shares of the medical research company’s stock valued at $1,374,000 after buying an additional 8,946 shares during the period. Avantax Advisory Services Inc. raised its holdings in Exact Sciences by 23.6% in the 1st quarter. Avantax Advisory Services Inc. now owns 6,588 shares of the medical research company’s stock valued at $285,000 after acquiring an additional 1,259 shares during the last quarter. Cetera Investment Advisers lifted its stake in shares of Exact Sciences by 6.8% during the 1st quarter. Cetera Investment Advisers now owns 88,233 shares of the medical research company’s stock worth $3,820,000 after purchasing an additional 5,596 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Exact Sciences by 12.4% during the 1st quarter. Mackenzie Financial Corp now owns 3,281,639 shares of the medical research company’s stock worth $142,062,000 after purchasing an additional 362,314 shares during the period. Finally, MJT & Associates Financial Advisory Group Inc. acquired a new stake in shares of Exact Sciences during the first quarter worth $149,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Exact Sciences Stock Performance

Exact Sciences stock opened at $100.67 on Friday. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $101.87. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56. The company has a market capitalization of $19.07 billion, a price-to-earnings ratio of -18.54, a price-to-earnings-growth ratio of 5.56 and a beta of 1.34. The firm’s fifty day moving average price is $61.91 and its 200 day moving average price is $55.11.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The company had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. During the same period last year, the firm earned ($0.21) earnings per share. The company’s revenue was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS. On average, research analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EXAS has been the subject of several analyst reports. Craig Hallum upped their target price on Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Guggenheim downgraded shares of Exact Sciences from a “buy” rating to a “neutral” rating in a research note on Thursday. BTIG Research lowered shares of Exact Sciences from a “buy” rating to a “neutral” rating in a report on Thursday. UBS Group lowered their target price on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, August 7th. Finally, Citigroup lowered shares of Exact Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.13.

Insider Buying and Selling

In other Exact Sciences news, EVP Brian Baranick sold 2,858 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total transaction of $200,288.64. Following the completion of the sale, the executive vice president owned 22,368 shares in the company, valued at $1,567,549.44. This trade represents a 11.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Edward Doyle sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director directly owned 57,962 shares in the company, valued at approximately $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.20% of the stock is owned by company insiders.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.